Home > Boards > Free Zone > Penny Fundamentals > Stock Room

$XCRT Head of Non-Standard Investments at FinTrust, Vincent

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AskMuncher Member Profile
 
Followed By 378
Posts 14,331
Boards Moderated 1
Alias Born 06/07/18
160x600 placeholder
AskMuncher   Friday, 04/30/21 10:38:02 AM
Re: None
Post # of 10336 
$XCRT Head of Non-Standard Investments at FinTrust, Vincent C. du Vigneaud, Joins Advisory Board of Xcelerate, Inc.
Press Release | 04/27/2021
Head of Non-Standard Investments at FinTrust, Vincent C. du Vigneaud, Joins Advisory Board of Xcelerate, Inc.
PR Newswire

MAULDIN, S.C., April 27, 2021

MAULDIN, S.C., April 27, 2021 /PRNewswire/ -- Xcelerate, Inc (OTC: "XCRT"), a rapidly emerging leader in assembling and developing early-stage medical technology today announced Vincent C. du Vigneaud has joined its Advisory Board.

du Vigneaud currently serves as Portfolio Manager/Analyst/ Trader and Head of Non-Standard Investments FinTrust Capital Advisors in Greenville, SC. FinTrust is an RIA and Investment Management firm with over $1.5 billion in client assets. Prior to joining FinTrust Vincent held various trading / operations positions with several fund management firms and co-founded SuNOVA Capital and Thesis Fund Management, both New York-based hedge funds.

"Vincent brings another invaluable skill set to our Advisory Board," said Michael O'Shea, Xcelerate' s CEO. "His 25 years of experience in financial analysis and capital structure, along with his knowledge of regulatory issues will be a tremendous aide in the next phase of our development plan which is to analyze business combinations and develop capital funding programs. duVigneaud also worked as an analyst and trader at Olayan America, the Family Office for the Olayan Family (over $10 billion net worth), said O'Shea.

About Xcelerate

Xcelerate is a company seeking innovative acquisitions within the patent/engineering world and focused on joining early-stage medical technology companies in a setting that is a controlled clinical care where these new developments can be trailed, tested and applied.

To interview either du Vigneaud or O'Shea, contact Justin Baronoff at 561-750-9800; Justin@transmediagroup.com.

SAFE HARBOR

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.

Cision View original content:http://www.prnewswire.com/news-releases/head-of-non-standard-investments-at-fintrust-vincent-c-du-vigneaud-joins-advisory-board-of-xcelerate-inc-301277615.html

SOURCE Xcelerate, Inc.



Hi my posts are for entertainment purposes only. Consult a professional. And if it lasts longer than 4 hours, call a physician with a good camera.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences